Reports
Reports
Sale
The global cancer therapeutics market size attained a value of USD 149.92 billion in 2023, driven by increase in research and development activities, rising cooperation among pharmaceutical companies, rising geriatric population, rising demand for personalised medicine, and increased investment in the healthcare sector. The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032 to attain a value of USD 365.25 billion by 2032.
The cancer therapeutics market is being driven by the increased investment by companies in the R&D sector. The increasing incidences of cancer across the globe are also adding to the cancer therapeutics market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer therapy includes the use and administration of chemotherapy and oncology drugs for the treatment of cancer. It is a type of treatment that identifies and attacks particular kinds of cancer cells with less damage to ordinary cells with the help of drugs or other substances. Some targeted therapies block certain enzymes, proteins, or other molecules that are engaged in cancer cell development.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The cancer therapeutics market can be divided on the basis of segments like application and top-selling drugs.
The industry can be broadly categorised based on its application into:
The cancer therapeutics market can be divided on the basis of its top-selling drugs as Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.
The EMR report looks into the regional cancer therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
An increase in the incidences of cancer, rising cooperation among pharmaceutical companies, and growing innovation in the cancer-research sector are factors that are driving the growth of the cancer therapeutics industry. It is anticipated that the geriatric population will increase over the forecast period, further increasing the demand for cancer therapy. Further, the rising demand for personalised medicine and increased investment in the healthcare sector, particularly in developing countries, is providing the cancer therapeutics market with new growth opportunities. Some of the factors that restrict cancer therapeutics market growth are high costs connected with oncology drug development and adverse effects associated with cancer therapy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global cancer therapeutics market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapy Type |
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Cancer Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Cancer Therapeutics Market Overview
6.1 Global Cancer Therapeutics Market Historical Value (2017-2023)
6.2 Global Cancer Therapeutics Market Forecast Value (2024-2032)
7 Global Cancer Therapeutics Market Landscape
7.1 Global Cancer Therapeutics Company Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Therapeutics Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Cancer Type
7.2.5 Analysis by Distribution Channel
8 Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Therapeutics Market Segmentation
11.1 Global Cancer Therapeutics Market by Therapy Type
11.1.1 Market Overview
11.1.2 Chemotherapy
11.1.3 Immunotherapy
11.1.3.1 Checkpoint Inhibitors
11.1.3.2 Car-T Cell Therapy
11.1.3.3 Cancer Vaccines
11.1.3.4 Cytokine Therapy
11.1.4 Targeted Therapy
11.1.4.1 Tyrosine Kinase Inhibitors
11.1.4.2 Monoclonal Antibodies
11.1.4.3 Proteasome Inhibitors
11.1.5 Hormonal Therapy
11.1.6 Radiation Therapy
11.1.7 Stem Cell Transplant
11.1.8 Gene Therapy
11.1.9 Other Emerging Therapies
11.2 Global Cancer Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Alkylating Agents
11.2.3 Antimetabolites
11.2.4 Antitumor Antibiotics
11.2.5 Topoisomerase Inhibitors
11.2.6 Mitotic Inhibitors
11.2.7 Hormone Therapies
11.2.8 Immune Checkpoint Inhibitors
11.2.9 Others
11.3 Global Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.3.4 Subcutaneous
11.3.5 Intramuscular
11.3.6 Topical
11.3.7 Others
11.4 Global Cancer Therapeutics Market by Cancer Type
11.4.1 Market Overview
11.4.2 Lung Cancer
11.4.3 Breast Cancer
11.4.4 Prostate Cancer
11.4.5 Colorectal Cancer
11.4.6 Skin Cancer
11.4.7 Blood Cancer (Leukemia, Lymphoma, etc.)
11.4.8 Gastrointestinal Cancer
11.4.9 Gynecological Cancer
11.4.10 Others
11.5 Global Cancer Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital pharmacies
11.5.3 Retail pharmacies
11.5.4 Online pharmacies
11.5.5 Specialty pharmacies
11.6 Global Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 AstraZeneca
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Bristol-Myers Squibb
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Eli Lilly and Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 GlaxoSmithKline
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Johnson & Johnson
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Merck & Co., Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis International AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Pfizer Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Sanofi
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Takeda Pharmaceutical Company Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Celgene Corporation
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Amgen Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Gilead Sciences, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Bayer AG
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 AbbVie Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Regeneron Pharmaceuticals, Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Genentech
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Seattle Genetics, Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Aimmune Therapeutics
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Global Cancer Therapeutics Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global market for cancer therapeutics reached a value of USD 149.92 billion.
The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032 to reach a value of USD 365.25 billion by 2032.
The major drivers of the market include the increase in research and development activities, rising cooperation among pharmaceutical companies, rising geriatric population, rising demand for personalised medicine, and increased investment in the healthcare sector.
Increasing incidences of cancer, and growing innovation in the cancer-research sector are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The cancer therapeutics market can be divided on the basis of its top-selling drugs into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.
Cancer therapeutics find their major application in sectors like blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, and melanoma, among others.
The major players in the industry are AbbVie Inc. , Astellas Pharma Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.